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Abstract
Acute flaccid myelitis (AFM) is characterized by flaccid paralysis of one or more limbs, often following a viral illness, with magnetic resonance imaging findings consistent with inflammation of the spinal cord gray matter. It is unclear whether all patients with AFM will have full recovery of neurologic function. Since 2014, there have been several clusters of AFM in the United States, with a 3-fold increase in reported AFM cases recorded in 2018 compared with the previous year. Epidemiological evidence supports a temporal association between respiratory enteroviral illness, particularly with enteroviruses D68 and A71, and clustering of AFM cases. However, causality has yet to be established. Treatment of AFM is primarily supportive. Adjunctive therapies such as intravenous immunoglobulin, corticosteroids, plasmapheresis, and fluoxetine have not been found to improve long-term outcomes. Further research is urgently needed to characterize and optimize management of this emerging, yet poorly understood, condition. 1 In this review, we highlight the epidemiology and clinical presentation of recent outbreaks and discuss the diagnosis and management of this emerging, yet poorly understood, condition in the United States and globally.
DEFINITIONS
Before widespread vaccination in the 1950s, poliovirus was the most common cause of acute flaccid paralysis (AFP) characterized by anterior myelitis. This condition was often referred to as poliomyelitis. The inclusion of imaging criteria in the case definition of AFM may provide greater specificity to the broader epidemiological case definition of AFP, which is primarily used for global poliovirus surveillance. In order to avoid confusion with this term, AFM will be used for the purposes of this review.
2,3
The case definition of confirmed AFM from the CDC since 2014 includes acute flaccid weakness of one or more limbs in individuals of any age and magnetic resonance imaging (MRI) showing a spinal cord lesion largely restricted to gray matter secondary to anterior myelitis (anterior horn cell/spinal cord involvement) and spanning one or more spinal segments. The classification for a probable case includes clinically compatible signs and symptoms and cerebrospinal fluid (CSF) pleocytosis (white blood cell count [WBC] >5/mL [to convert to Â10 9 /L, multiply by 0.001]). 4 
EPIDEMIOLOGY AND POTENTIAL ETIOLOGIES
In the current era, nonpolio enteroviruses (EVs) are most often implicated in causing AFM, reflecting successful and widespread implementation of vaccination against poliovirus globally. Overall, the estimated incidence of AFM is rare at less than 1 per million, and it typically affects previously healthy children with a slight male preponderance. 1, 5 In a recent report from a 2018 outbreak (among 80 confirmed cases from January 1 through November 2, 2018, in the United States), during the 4 weeks preceding the onset of limb weakness, signs and symptoms consistent with a viral illness were reported in 79 (99%) individuals. These symptoms included fever in 65 patients (81%), respiratory symptoms (eg, cough, rhinorrhea, and congestion) in 62 (78%), and gastrointestinal symptoms (eg, vomiting and diarrhea) in 30 (38%) with confirmed AFM. 1 Epidemiological evidence from this outbreak supports a temporal association between respiratory EV illness, particularly with EV-D68 and EV-A71 and clustering of AFM cases. 1, 6 Since the elimination of wild-type poliovirus from the Western Hemisphere in 1991, 7 other reported potential sporadic causes of AFM have implicated flaviviruses such as West Nile and Japanese encephalitis viruses, 8, 9 herpesviruses, 10 and adenoviruses. 11 At a cellular level, the pathogenesis of AFM remains unclear, but the clinical presentation may reflect postinfectious immune responses to these viruses with accompanying inflammatory damage to gray matter. Alternatively, these viruses may cause direct neuronal damage in susceptible hosts, whose underlying risk factors for invasive disease are yet to be determined.
RECENT CLUSTERS OF AFM IN THE UNITED STATES

2012-2015
In late summer and fall of 2014, 120 pediatric cases of AFM were reported to the CDC from 34 US states, coinciding with a national outbreak of EV-D68eassociated respiratory illness. Because routine national surveillance data on AFP and AFM before this outbreak were not available, the CDC could not confirm a true increase in cases over previous years. These AFM cases were temporally associated with increases in respiratory illnesses secondary to EV-D68. 9 The median age at presentation was 7.1 years, 59% were male, and 81% experienced respiratory or febrile (64%) symptoms before the onset of limb weakness. Cervical spinal cord abnormalities were noted by MRI in 103 of 118 patients (87%), with CSF pleocytosis noted in 81%. Among 55 CSF specimens analyzed by polymerase chain reaction, only 1 was positive for EV-D68. One CSF specimen was also positive for Epstein-Barr virus; however, this CSF specimen had more than 3000/mL red blood cells, which may reflect contamination with blood. Enterovirus D68 was detected in 20% of upper respiratory tract specimens, with detection rates improving to 47% with specimens collected 7 or fewer days from onset of respiratory illness/fever. Twenty percent of patients required mechanical ventilation for neuromuscular respiratory failure. During follow-up of 56 individuals at 4 months, 8 (14%) were completely dependent on caregivers, 38 (68%) had some degree of functional impairment, and 10 (18%) reported being fully functional. Only 3 patients (5%) reported complete recovery of strength. No deaths were reported. 9 This study was preceded by 59 cases of "AFP" reported by the California Department of Public Health from June 2012 through July 2015. The median age of presentation was 9 years, with most patients experiencing respiratory or gastrointestinal illness before or concurrent with muscle flaccidity. Of the 59 cases, 56 had hyperintensity of spinal gray matter on T2-weighted imaging, and 43 of 59 cases had CSF pleocytosis. Two immunocompromised adults died within 60 days of symptom onset. Enteroviruses were most frequently detected in either nasopharynx swab or stool specimens or in serum samples (15 of 45 patients tested). No potential pathogens were detected in CSF. However, the incidence of reported cases was significantly higher during a national EV-D68 outbreak from August 2014 through January 2015 compared with other monitoring periods. 12 Messacar et al 13 reported on the first geographic and temporal cluster of AFM and cranial nerve dysfunction associated with a community-wide outbreak of EV-D68 respiratory disease in 12 children who met the case definition between August 1 and October 31, 2014. Neurologic deficits included flaccid limb weakness (n¼10; asymmetric, n¼7), bulbar weakness (n¼6), and cranial nerve VI (n¼3) and VII (n¼2) dysfunction. Ten children (83%) had confluent, longitudinally extensive spinal cord lesions of the central grey matter with predominant anterior horn cell involvement, and 9 children (75%) had brain stem lesions. Ten of 11 children (91%) had CSF pleocytosis. Nasopharyngeal specimens from 8 of 11 children (73%) were positive for rhinovirus or EV. Viruses from 5 of 11 children (45%) were typed as EV-D68. Results of EV polymerase chain reaction of CSF, blood, and rectal swabs and tests for other causes were negative. Improvement of cranial nerve dysfunction was noted in 3 of 10 children (30%). All 10 children with limb weakness continued to experience residual deficits.
2016-2018
In 2016, 149 confirmed cases of AFM were reported compared with 22 in 2015 and 33 in 2017 across 16 states. In 2018 (from January 1-November 2), 106 suspected cases of acute flaccid limb weakness were reported. Of these, 80 were classified as confirmed cases of AFM and 6 as probable, a 3-fold increase compared with 2017. 
OUTBREAKS OUTSIDE THE UNITED STATES
Since the reports of AFM cases in 2014 in Colorado and California, there have been reports of AFM cases outside the United States, including in Canada and several European countries (France, Scotland, Sweden, Norway, and Spain), Argentina, and Japan. [16] [17] [18] [19] These reports further support an association between AFM cases and EV-D68 respiratory and gastrointestinal infections, with virus often detected in respiratory specimens.
ETIOLOGIES: ASSOCIATIONS WITH EV-D68 AND EV-A71
Enterovirus D68
The cause of recent cases of AFM remains unclear, although EVs are strongly implicated, particularly EV-D68. Enterovirus D68 is closely related to rhinoviruses and has a predilection for the upper respiratory tract. Increased circulation in 2014 and 2016 of EV-D68 was temporally and geographically associated with increases in cases of AFM and was often detected in respiratory specimens of affected patients in the United States 1, [12] [13] [14] [16] [17] [18] and globally. [15] [16] [17] [18] Among the reports of clusters of AFM in 2014 in the United States, a temporal and geographic association with hospitalizations for severe respiratory illness in children with EV-D68 infection has been well documented. 9, 12, 13 However, no causality has been established. One review of the 2014 cases of AFM demonstrated detection of EV-D68 in only 20% of upper respiratory tract specimens. 9 In addition, the absence of direct virus detection from affected tissues and infrequent detection in CSF has left the causal nature of this relationship unproven. By applying the Bradford Hill criteria to determine a putative association between EV-D68 and AFM, Messacar et al 20 recently reported on a causal relationship, through fulfillment of strength, consistency, temporality, plausibility, coherence, experiment, and analogy criteria. Furthermore, they suggest that if a causal relationship exists, AFM is an infrequent manifestation of EV-D68 infection and is one of several pathogens to cause the condition. They concluded that prospective epidemiological studies with appropriately timed collection of specimens from all relevant anatomic sites (respiratory, stool, rectal, blood, CSF, and central nervous system tissue) for virologic, serologic, and immunologic analyses were needed to further define the role of EV-D68 in AFM.
Enterovirus A71
Enterovirus A71 is closely related to polioviruses and can cause a wide range of clinical presentations including hand, foot, and mouth disease, systemic disorders including pulmonary edema and respiratory collapse, and neurologic disease. The neurologic manifestations of EV-A71 include aseptic meningitis, AFP similar to poliomyelitis, and brain stem encephalitis. 21 Epidemics of neurologic disease including AFP have occurred in Europe, South America, and the Asia-Pacific region (most recently in the early 2000s). 21 In 1997, a large outbreak of 2618 cases of hand-foot-mouth disease occurred in Sarawak, Malaysia, and resulted in 34 deaths. In 1998, an epidemic in Taiwan affected 1.5 million people, with 405 children hospitalized because of serious neurologic complications. 22 Outbreaks like these have continued to occur in the Asia-Pacific region with continued cases associated with neurologic disease, which includes AFP. 23 
CLINICAL PRESENTATION
The clinical presentation of AFM is divided into 3 stages: prodromal illness, acute neurologic injury, and the convalescent phase. The prodromal phase for most patients involves a febrile illness approximately 1 week (but up to 4 weeks) before onset of neurologic symptoms. Most patients reported upper respiratory tract symptoms such as cough, rhinorrhea, and congestion. Some patients with AFM may have gastrointestinal symptoms such as vomiting or diarrhea during the prodromal period as well. The likely viral prodromal illness typically begins to resolve before onset of neurologic signs and symptoms. Acute neurologic injury often involves early onset of flaccid limb weakness consistent with lower motor neuron disease. Symptoms include recurrence of fever, myalgia, and flaccid weakness in at least one limb for most patients. 12, 13 The onset of neurologic symptoms can be rapid, occurring within hours or more prolonged over a number of days with a median time to neurologic nadir of 4 days. Limb weakness can be classified as flaccid with decreased reflexes. There has been a wide range of neurologic severity ranging from mild weakness (4 out of 5 strength) to complete paralysis. Upper extremities seem to be affected more than lower extremities. The number of limbs affected ranges from 1 to all 4, typically with an asymmetric presentation. No changes in sensation were reported in patients from California and Colorado, 12, 13 whereas CDC surveillance reported decreased sensation in about 25% of patients. Bowel and bladder dysfunction were also variably reported among studies, as was altered mental status and cranial nerve dysfunction. Although cranial nerve dysfunction is not part of the case definition of AFM, bulbar palsy has been noted in AFM cases reported by the California Department of Public Health Surveillance and CDC surveillance. 5, 12, 13 The convalescent phase may span months to years, with many patients experiencing residual muscle weakness and atrophy. It is unclear at the present time whether all patients with AFM will have a complete recovery in neurologic function and how long this recovery will take.
DIAGNOSIS
The diagnosis of AFM involves the appropriate clinical presentation of acute-onset flaccid limb weakness. For a case to meet the CDC case definition for AFM, the patient must either have MRI of the brain and spinal cord findings consistent with spinal cord gray matter involvement (Figure 2 ) as discussed previously or CSF pleocytosis (WBC >5/mL) with or without elevated protein level.
In a review of AFM cases in the United States from 2012 to 2015, most patients had mild-moderate CSF pleocytosis (median WBC, 44/mL) with a lymphocytic predominance. The CSF protein level was also mildly elevated with a median of 43 mg/dL (to convert to g/L, multiply by 0.01). In most cases, the CSF glucose level was normal. Oligoclonal and antieaquaporin-4 antibodies were absent in all tested patients. In this same review, MRI revealed nonenhancing lesions of the spinal cord gray matter on T2-weighted imaging. Most patients (90% in one cohort) had lesions spanning least 3 vertebral levels. 5 All cases of AFM reported to the CDC are tested for EV/rhinovirus if specimens are available. Further testing should include appropriately timed collection of specimens from all relevant anatomic sites (nasopharynx, throat, stool, rectal, blood, CSF, and CNS tissue) for EV-D68, EV-A71, and other EVs using appropriate virologic, serologic, and immunologic assays. Arbovirus, adenovirus, and herpesvirus testing should be considered. Immune markers such as oligoclonal and antieaquaporin-4 antibodies may help with testing. All suspected cases should be reported to state health departments and to the CDC.
MANAGEMENT
The mainstay of management for most cases of AFM is primarily supportive. Adjunctive therapies have included intravenous immunoglobulin (IVIG), high-dose corticosteroids, plasmapheresis, or a combination of these treatments. These adjunct therapies have no demonstrated efficacy based on clinical trials but have been provided to patients because their potential benefits outweigh their risks. In cases of suspected AFM, we suggest supportive therapies and consideration for a trial of IVIG or corticosteroids. Our practice has preferred the use of IVIG over corticosteroids to avoid immunosuppression in the setting of a concern for the neurologic findings of AFM being secondary to an active infectious process rather than a postinfectious inflammatory process. We would suggest consultation with infectious disease and neurology teams in the management of all suspected AFM cases.
Antiviral agents tested thus far do not appear to have activity against the circulating strains of EV-D68. Fluoxetine was found to have in vitro activity against EV-D68. A recent study on the use of fluoxetine in patients with AFM found that fluoxetine was well tolerated and safe. However, this intervention was not associated with improved neurologic outcomes. 24 The convalescent phase of AFM lasts months to years with lingering or residual weakness. The long-term prognosis of AFM is unknown. Long-term therapy involves rehabilitation and physical therapy.
CONCLUSION
Acute flaccid myelitis is characterized by flaccid weakness in one or more limbs accompanied by either MRI findings of spinal cord gray matter involvement or CSF pleocytosis. The United States is experiencing another outbreak of AFM cases, with a 3-fold increase in the number of possible AFM cases reported to the CDC in 2018 compared with 2017. Despite several outbreaks of AFM since 2014 and evidence of a temporal association with nonpolio EV outbreaks, the cause of AFM is still unknown. Most cases of AFM are preceded by symptoms consistent with a viral illness followed by onset of neurologic symptoms and a convalescent phase characterized by residual weakness and neurologic injury. Suspected cases of AFM should be reported to the CDC and state health departments. The management of AFM remains supportive. Further research is urgently needed to understand this emerging, yet poorly understood, condition.
